{"filing":{"accession_number":"0001104659-26-084617","cik":"0001829635","ticker":"RNAZ","company_name":"Transcode Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-17","report_date":null,"primary_document":"tm2620727d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/tm2620727d1_8k.htm"},"events":[{"id":18677,"run_id":16795,"accession_number":"0001104659-26-084617","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"summary":"Transcode Therapeutics amended the Certificate of Designation for Series C Preferred Stock, increasing the beneficial ownership limitation from 4.99% to 9.99% and correcting scrivener's errors. The amendment was approved by the Board and Series C holders.","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-07-17","form":"8-K","submitted_at":null,"items":[{"id":17556,"accession_number":"0001104659-26-084617","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"Item 3.03 discloses a material modification to rights of securityholders by incorporating Item 5.03 by reference. Item 5.03 typically covers amendments to articles of incorporation or bylaws. Without the full text of Item 5.03, the specific nature of the modification cannot be determined, but any material modification to securityholder rights is governance-related and material to investors' assessment of their ownership interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T20:07:14.979251+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17557,"accession_number":"0001104659-26-084617","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns an amendment to the Certificate of Designation for Series C Preferred Stock, increasing the beneficial ownership limitation from 4.99% to 9.99% and correcting scrivener's errors. While the amendment was approved by the Board and Series C holders, it is a routine governance/corporate structure matter with no new securities issued and no substantive operational or financial impact. The filing is administrative in nature and would not materially affect a reasonable investor's assessment of the registrant's financial condition or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T20:07:14.979251+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17556,"accession_number":"0001104659-26-084617","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"Item 3.03 discloses a material modification to rights of securityholders by incorporating Item 5.03 by reference. Item 5.03 typically covers amendments to articles of incorporation or bylaws. Without the full text of Item 5.03, the specific nature of the modification cannot be determined, but any material modification to securityholder rights is governance-related and material to investors' assessment of their ownership interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T20:07:14.979251+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-07-17"},{"id":17557,"accession_number":"0001104659-26-084617","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns an amendment to the Certificate of Designation for Series C Preferred Stock, increasing the beneficial ownership limitation from 4.99% to 9.99% and correcting scrivener's errors. While the amendment was approved by the Board and Series C holders, it is a routine governance/corporate structure matter with no new securities issued and no substantive operational or financial impact. The filing is administrative in nature and would not materially affect a reasonable investor's assessment of the registrant's financial condition or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T20:07:14.979251+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-07-17"}]}